AzTrials
AzTrials

InflammationTDEBCNCT00910026

Study of the Influence of Various Tidal Volumes on Exhaled Breath Condensate (EBC) in Mechanically Ventilated Patients

A study testing low tidal volume ventilation and high tidal volume ventilation in people with Inflammation, run by Larissa University Hospital at 1 site in Greece.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The aim of the present study is to evaluate the effect of low (6 ml/kg) and high (12 ml/kg) tidal volume ventilation on inflammatory and oxidative stress biomarkers in the exhaled breath condensate (EBC) of ICU patients without lung injury. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Inflammation
What is being tested?
low tidal volume ventilation and high tidal volume ventilation
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
1 siteGreece
Study dates
May 2009to Sep 2013
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • ICU patients mechanically ventilated because of stroke, subarachnoid and/or intracerebral hemorrhage
  • Healthy respiratory system

Who cannot join

  • Pulmonary diseases

Trial locations and contacts

1 site in 1 country.

Greece1 site
  • Intensive Care Unit Department of University Hospital of Larissa

    Larissa, Thessaly, 41110

Other trials in Greece

About this study

Official title: Exhaled Breath Condensate (EBC) Collection and Analysis in Mechanically Ventilated ICU Patients: Monitoring of the Influence of Various Tidal Volumes on Lung Inflammatory Biomarkers

The aim of the present study is to evaluate the effect of low (6 ml/kg) and high (12 ml/kg) tidal volume ventilation on inflammatory and oxidative stress biomarkers in the exhaled breath condensate (EBC) of ICU patients without lung injury. As the analysis of EBC is reflecting the composition of epithelial lining fluid (ELF), the study of EBC pH and inflammatory and oxidative stress markers could have the potential for assessing lung inflammation caused by mechanical ventilation. This study also aims to look at the possibility to identify selective profiles of biomarkers that might have a prognostic and/or diagnostic value in the follow up of these patients.

Read the detailed description

INTRODUCTION:

Airway inflammation plays a key role in many airway diseases. Non invasive methods to study these inflammatory processes and to monitor airway diseases are in high demand. Stimulating interest is in breath analysis, such as the analysis of exhaled breath condensate (EBC), a technique of sampling the epithelial lining fluid of the lung (ELF), as an even easier way to assess airway inflammation (1,2). The appeal of EBC lies in its ability to collect non-invasively a wide range of nonvolatile molecules from the respiratory tract, the fact that it can be repeated frequently within short intervals without adverse events and that collection devices can be used in a wide range of settings including intensive care units (3,4,5,6).

Analysis of EBC could not be limited to patient monitoring and understanding mechanisms of pulmonary disease. It also could become a useful tool for monitoring and screening for healthy individuals for possible early pulmonary tissue damage (6,7). There is a special need for more data on intra-subject and day-to-day variation, both essential for the decision as to whether a biomarker can serve as a research tool or even has the potential for disease monitoring in clinical practice (7).

It has been recognized for some time that mechanical ventilation may induce lung injury and inflammation (8,9,10). Recent experimental and clinical data suggest that in healthy lungs, mechanical ventilation with tidal volume ranging between 7 and 12 ml/kg in the absence of positive end-expiratory pressure may lead to endothelial, extracellular matrix and peripheral airways damage without major inflammatory response, which further worsen with higher tidal volumes (15,34). Several mechanisms may explain damage to the lung structure induced by mechanical ventilation: regional over distension, 'low lung volume' associated with tidal airway closure, and inactivation of surfactant (15).

High tidal volume ventilation has been shown to result in increased mortality while low tidal volume ventilation is regarded as a lung protective strategy in ALI, ARDS (11,12,13,35).

In contrast, in other randomized studies (31,32) including a heterogeneous group of major thoracic and abdominal surgical procedures, protective mechanical ventilation was not associated with a decrease in intrapulmonary and systemic inflammation. Furthermore, there was no evidence that protective ventilation prevented lung adverse effect or decreased systemic cytokine levels in cardiac surgery (33).

In line with these observations and considering that a practical parameter of increased mechanical stress of the lung remains to be demonstrated, studies may address the question whether the analysis of EBC biomarkers are related to ventilator-induced lung injury by low or high tidal volumes.

MATERIALS AND METHODS:

The present study is a prospective, randomized, controlled trial that will take place in the ICU of the University Hospital of Larissa, Thessaly. Authorization has been given from the Scientific Council and the ethical committee of our hospital.

Patients:

ICU patients requiring mechanical ventilation because of stroke, subarachnoid and/or intracerebral hemorrhage and with healthy respiratory system (evaluated using criteria as the LISS - Murray Lung Injury Severity Score) (14).

Interventions:

EBC collection will be performed on mechanically ventilated patients through the endotracheal tube according to ATS/ERS task force 2005 (7). Patients must be hemodynamically and respiratory stable.

All patients will be under sedation and will receive ventilation by volume control. The respiratory frequency will be adapted at the set tidal volume in order to maintain the pH values within normal limits (7.35-7.45). SaO2 will be maintained equal or superior to 95%.

EBC will be collected by inserting a special conduit (FILT, lung and chest diagnostics Ltd. Berlin Germany) for the breath condensate collecting device (Ecoscreen, Jaeger, Germany) into the expiratory limb of the ventilator tubing. Collecting time for EBC will be 30 min. No humidification will be used during the collection.

The acidity (pH) of EBC before and after de-aeration with an inert gas Argon, 350 ml/minutes for 10 minutes, (gas standardisation) (17) will be readily measured using a pH meter Jenway Model 3510.

All samples will be stored at -80 ο C for subsequent mediator measurements. Variables of ventilation (frequency, PEEP, FIO2, Vt), lung mechanics, arterial pressure, heart rate, arterial blood saturation, ICP and gas blood samples examination will be registered before and during the EBC collection. Also will be registered indices of lung injury (PiO2/FiO2, LISS), indices of systemic inflammation (temperature, leucocyte and neutrophil counts in blood samples) during the observation period. Disease severity indices (SOFA, SAPS, APACHE II) will be registered during the initial assessment.

EBC analysis:

EBC collected will be analyzed for pH, 8-isoprostane, H2O2, nitrites/nitrates and cytokines. The measurement of biomarkers will be performed using standardized procedures, as previously described.

pH measurements: pH will be measured as previously described (16,17). H2O2 measurements: H2O2 concentration will be determined by an enzymatic assay using horseradish peroxidase (Sigma Chemicals, St. Louis, MO), as previously described (17,18,19,20).

8-Isoprostane measurements: 8-Isoprostane will be determined by a competitive enzyme immunoassay kit (Cayman Chemical, Ann Arbor, MI), as previously described (17,18,21,29). The detection limit of the assay is 4 pg/ml.

Nitrogen oxides, nitrite/nitrate (NO2/NO3), and related products measurements: will be performed as previously described (17,22). Briefly, will be determined by using spectrophotometric assays (Griess reaction) (23,24,25,26,27,28).

Cytokines measurement: will be quantified by EIA/ELISA kits as previously described (24,25,29,30).

Protocol Details:

The patients after the initial assessment will be randomized to receive mechanical ventilation with 6 or 12 ml/Kg of ideal body weight calculated through the following equation:

For men [(Height (cm)-154) x 0.9] +50 and For women [(Height (cm)-154) x 0.9] +45.5. The observation period will be a minimum of 10 days (if possible) and EBC collection will be performed within the first 24 hours of admission (day 0) and through the days 1,2,4,6,8,10.

EBC collection at day 0 will be performed under both modalities of ventilation with the purpose to investigate the quantity and composition of the collected EBC from the same patient ventilated with different tidal volumes. For the next measurements, the EBC collection for each group will be performed under the preset conditions of ventilation.

Complications such as VAP, ARDS or sepsis during the period of observation will be recorded.

Statistical analysis:

Analysis will be performed using SPSS for Windows v. 16.0. Normality of distribution will be checked with Kolmogorov-Smirnov test. Normally distributed data will be presented as mean ± standard deviation (SD), whereas skewed data as median (interquartile range). Comparisons between two groups will be evaluated with unpaired t tests for normally distributed and Mann-Whitney tests for skewed data. Comparisons between more than two groups will be performed with analysis of variance (ANOVA) with appropriate post hoc tests

Conditions
Inflammation
Being tested
low tidal volume ventilation, high tidal volume ventilation
Keywords
EBC and mechanical ventilation, low tidal volume ventilation, high tidal volume ventilation, inflammatory and oxidative stress EBC biomarkers, Ventilator induced lung injury
Medical subject headings
Inflammation, Ventilator-Induced Lung Injury

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • low tidal volume ventilationProcedure or surgery

    6 ml/kg tidal volume ventilation

  • high tidal volume ventilationProcedure or surgery

    12 ml/kg tidal volume ventilation

Study groups in NCT00910026
Study groupRoleWhat they receive
low tidal volume ventilationExperimental6 ml/kg tidal volume ventilation
Receives: Procedure: low tidal volume ventilation
high tidal volume ventilationExperimental12 ml/kg tidal volume ventilation
Receives: Procedure: high tidal volume ventilation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Evaluation of the effect of low (6 ml/kg) and high (12 ml/kg) tidal volume ventilation on inflammatory and oxidative stress biomarkers in the exhaled breath condensate (EBC) of ICU patients without lung injury.

    Measured: 2 years

Secondary outcomes (1)
  1. Evaluation of the prognostic role of exhaled biomarkers in the subsequent outcome of mechanically ventilated patients (length of ICU hospitalization, subsequent development of ALI or ARDS and morbidity and mortality in the ICU).

    Measured: 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 May 2009 (estimated)
  2. Study startMay 2009
  3. Primary completionSep 2013
  4. Study completionSep 2013

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Investigator
Enrolment
20 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00910026
Sponsor's protocol ID
4163/02-09-2008
Acronym
TDEBC
Status last verified
Nov 2009
First submitted
28 May 2009
Last updated
25 Oct 2013
Results posted
No
Data monitoring committee
No

Publications

  • Holz O. Catching breath: monitoring airway inflammation using exhaled breath condensate. Eur Respir J. 2005 Sep;26(3):371-2. doi: 10.1183/09031936.05.00071305. No abstract available.

    PubMed 16135713
  • Hunt J. Exhaled breath condensate: an evolving tool for noninvasive evaluation of lung disease. J Allergy Clin Immunol. 2002 Jul;110(1):28-34. doi: 10.1067/mai.2002.124966.

    PubMed 12110814
  • Mutlu GM, Garey KW, Robbins RA, Danziger LH, Rubinstein I. Collection and analysis of exhaled breath condensate in humans. Am J Respir Crit Care Med. 2001 Sep 1;164(5):731-7. doi: 10.1164/ajrccm.164.5.2101032. No abstract available.

    PubMed 11549524
  • Kharitonov SA, Barnes PJ. Exhaled markers of pulmonary disease. Am J Respir Crit Care Med. 2001 Jun;163(7):1693-722. doi: 10.1164/ajrccm.163.7.2009041. No abstract available.

    PubMed 11401895
  • Muller WG, Morini F, Eaton S, Peters M, Jaffe A. Safety and feasibility of exhaled breath condensate collection in ventilated infants and children. Eur Respir J. 2006 Sep;28(3):479-85. doi: 10.1183/09031936.06.00063505. Epub 2006 Apr 26.

    PubMed 16641124
  • Moloney ED, Mumby SE, Gajdocsi R, Cranshaw JH, Kharitonov SA, Quinlan GJ, Griffiths MJ. Exhaled breath condensate detects markers of pulmonary inflammation after cardiothoracic surgery. Am J Respir Crit Care Med. 2004 Jan 1;169(1):64-9. doi: 10.1164/rccm.200307-1005OC. Epub 2003 Oct 9.

    PubMed 14551168
  • Horvath I, Hunt J, Barnes PJ, Alving K, Antczak A, Baraldi E, Becher G, van Beurden WJ, Corradi M, Dekhuijzen R, Dweik RA, Dwyer T, Effros R, Erzurum S, Gaston B, Gessner C, Greening A, Ho LP, Hohlfeld J, Jobsis Q, Laskowski D, Loukides S, Marlin D, Montuschi P, Olin AC, Redington AE, Reinhold P, van Rensen EL, Rubinstein I, Silkoff P, Toren K, Vass G, Vogelberg C, Wirtz H; ATS/ERS Task Force on Exhaled Breath Condensate. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J. 2005 Sep;26(3):523-48. doi: 10.1183/09031936.05.00029705.

    PubMed 16135737
  • Thammanomai A, Majumdar A, Bartolak-Suki E, Suki B. Effects of reduced tidal volume ventilation on pulmonary function in mice before and after acute lung injury. J Appl Physiol (1985). 2007 Nov;103(5):1551-9. doi: 10.1152/japplphysiol.00006.2007. Epub 2007 Aug 9.

    PubMed 17690203
  • Halter JM, Steinberg JM, Gatto LA, DiRocco JD, Pavone LA, Schiller HJ, Albert S, Lee HM, Carney D, Nieman GF. Effect of positive end-expiratory pressure and tidal volume on lung injury induced by alveolar instability. Crit Care. 2007;11(1):R20. doi: 10.1186/cc5695.

    PubMed 17302983
  • Del Sorbo L, Slutsky AS. Year in review 2007: Critical Care--respirology. Crit Care. 2008;12(5):231. doi: 10.1186/cc6953. Epub 2008 Oct 14.

    PubMed 18983706
  • Dreyfuss D, Saumon G. From ventilator-induced lung injury to multiple organ dysfunction? Intensive Care Med. 1998 Feb;24(2):102-4. doi: 10.1007/s001340050529. No abstract available.

    PubMed 9539065
  • Parker JC, Hernandez LA, Peevy KJ. Mechanisms of ventilator-induced lung injury. Crit Care Med. 1993 Jan;21(1):131-43. doi: 10.1097/00003246-199301000-00024.

    PubMed 8420720
  • Amato MB, Barbas CS, Medeiros DM, Magaldi RB, Schettino GP, Lorenzi-Filho G, Kairalla RA, Deheinzelin D, Munoz C, Oliveira R, Takagaki TY, Carvalho CR. Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med. 1998 Feb 5;338(6):347-54. doi: 10.1056/NEJM199802053380602.

    PubMed 9449727
  • Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis. 1988 Sep;138(3):720-3. doi: 10.1164/ajrccm/138.3.720. No abstract available.

    PubMed 3202424
  • Pelosi P, Negrini D. Extracellular matrix and mechanical ventilation in healthy lungs: back to baro/volotrauma? Curr Opin Crit Care. 2008 Feb;14(1):16-21. doi: 10.1097/MCC.0b013e3282f25162.

    PubMed 18195621

Questions about this trial

What is this clinical trial studying?

A study testing low tidal volume ventilation and high tidal volume ventilation in people with Inflammation, run by Larissa University Hospital at 1 site in Greece.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 25 Oct 2013. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Greece. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Evaluation of the effect of low (6 ml/kg) and high (12 ml/kg) tidal volume ventilation on inflammatory and oxidative stress biomarkers in the exhaled breath condensate (EBC) of ICU patients without lung injury. (time frame: 2 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00910026, which also lists 35 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Oct 2013.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in